Tanya Clark
Leeds, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13).
Journal: BMJ open gastroenterology
Published: January 04, 2023
A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.
Journal: Alimentary pharmacology & therapeutics
Published: June 17, 2021
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results.
Journal: Inflammatory intestinal diseases
Published: October 02, 2020
Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
Journal: Scandinavian journal of gastroenterology
Published: April 25, 2018
Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
Journal: Inflammatory bowel diseases
Published: November 16, 2017
Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn's Disease.
Journal: Journal of Crohn's & colitis
Published: September 26, 2015
Long-term efficacy and safety of azathioprine in ulcerative colitis.
Journal: Journal of Crohn's & colitis
Published: December 18, 2014
Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.
Journal: Journal of Crohn's & colitis
Published: August 14, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026